ClinicalTrials.gov
public full text
Public Domain
Phase 2b Study of GSK4532990 in Adults With NASH
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer#1151045
- Study of GSK1363089 in Metastatic Gastric Cancer#1163799
- To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase#863070
- Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia#867977
- A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors#911509
Record · ID 1058124
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive